A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

NCT04955262 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Did not initiate due to business reasons. IND is inactive.

Conditions

Metastatic Melanoma

Interventions

BIOLOGICAL: Bempegaldesleukin (NKTR-214)
BIOLOGICAL: Nivolumab
DRUG: ⁸⁹Zr-Df-IAB22M2C

Sponsor

Nektar Therapeutics

Collaborators

[object Object]